.Pharmacolibrary.Drugs.D_Dermatologicals.D01B_AntifungalsForSystemicUse.D01BA01_Griseofulvin.Griseofulvin .Pharmacolibrary.Drugs.D_Dermatologicals.D01B_AntifungalsForSystemicUse.D01BA01_Griseofulvin.Griseofulvin| name: | Griseofulvin |
| ATC code: | D01BA01 | route: | oral |
| n-compartments | 1 |
Griseofulvin is an antifungal medication primarily used to treat dermatophytic infections (skin, hair, nails) caused by Trichophyton, Microsporum, and Epidermophyton species. It inhibits fungal cell mitosis by interfering with microtubule function. Griseofulvin is approved and used in human medicine, although its use has declined due to newer antifungal agents.
Pharmacokinetic parameters were reported in healthy adult volunteers after oral administration of griseofulvin micronized tablets.
Gupta, AK, et al., & Cooper, EA (2003). The efficacy and safety of terbinafine in children. Journal of the European Academy of Dermatology and Venereology : JEADV 17(6) 627–640. DOI:10.1046/j.1468-3083.2003.00691.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/14761128
Silva, MI, et al., & Halbert, GW (2023). Fed intestinal solubility limits and distributions applied to the Developability classification system. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 186 74–84. DOI:10.1016/j.ejpb.2023.03.005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36934829
Gupta, AK, et al., & Tavakkol, A (2005). The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence. Journal of drugs in dermatology : JDD 4(3) 302–308. PUBMED:https://pubmed.ncbi.nlm.nih.gov/15898285